Category - Markets

BTIG initiated coverage of Oxford Immunotec Global (NASDAQ:OXFD) with a “buy” rating and $21 price target. The stock closed at $16.76 on Sept. 27. Oxford already has a successful product – TSPOT.TB test, which is...

Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26. Savara is developing inhalable formulations of therapeutics with proven...

H.C. Wainwright raised its price target for Fibrocell Science (NASDAQ:FCSC) to $7.60 from $5.70 after the company announced first efficacy data from a single injection of FCX-007 in patients with recessive dystrophic...

H.C. Wainwright initiated coverage of Corium International (NASDAQ:CORI) with a “buy” rating and $15 price target. The stock closed at $10.88 on Sept. 25. Corium is a pure-play transdermal (TD) patch dug delivery...

Leerink upgraded for Dova Pharmaceuticals (NASDAQ:DOVA) to “outperform” from “market perform” and raised its price target to $32 from $24 after competitor, Shionogi, announced results from a Phase 3 trial. Shares of...

Roth Capital Partners launched coverage of AIT Therapeutics (OTC:AITB) with a “buy” rating and $14 price target. The stock closed at $5.75 on Sept. 25. AIT is utilizing nitric oxide-based inhalation technology to treat...

Stifel downgraded Genocea Biosciences (NASDAQ:GNCA) to “hold” from “buy” and slashed its price target to $2.50 from $15 after the company shifted its strategic focus. The stock closed at $5.33 on Sept. 25. “We believe...

Canaccord Genuity upgraded STAAR Surgical (NASDAQ:STAA) to “buy” from “hold” and raised its price target to $15 from $11, suggesting a resolution to a FDA warning letter soon. The stock closed at $10.90 on Sept. 22...

William Blair upgraded Akari Therapeutics (NASDAQ:AKTX) to “outperform” from “market perform” after the company announced that, following its end-of-Phase-2 meeting with the FDA, it is advancing Coversin for the...

Profound Medical (TSXV:PRN; OTCQX:PRFMF) closed a bought deal financing for total proceeds of $10-million. The company sold 10 million units at a price of $1 each, with each unit consisting of one common share of...